<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Deshpande, Mukund V.</style></author><author><style face="normal" font="default" size="100%">Kulkarni, Shuklangi A.</style></author><author><style face="normal" font="default" size="100%">Ghormade, Vandana</style></author><author><style face="normal" font="default" size="100%">Kapoor, Manisha</style></author><author><style face="normal" font="default" size="100%">Chavan, Santosh B.</style></author><author><style face="normal" font="default" size="100%">Kulkarni, Grish</style></author><author><style face="normal" font="default" size="100%">Shouche, Yogesh</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Development of mycoinsecticide for the control of insect pests: comparative evaluation of metarhizium isolates to identify strains for commercialization</style></title><secondary-title><style face="normal" font="default" size="100%">New Biotechnology</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2009</style></year><pub-dates><date><style  face="normal" font="default" size="100%">SEP</style></date></pub-dates></dates><number><style face="normal" font="default" size="100%">1</style></number><publisher><style face="normal" font="default" size="100%">ELSEVIER SCIENCE BV</style></publisher><pub-location><style face="normal" font="default" size="100%">PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS</style></pub-location><volume><style face="normal" font="default" size="100%">25</style></volume><pages><style face="normal" font="default" size="100%">S88-S89</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><custom3><style face="normal" font="default" size="100%">Foreign</style></custom3><custom4><style face="normal" font="default" size="100%">1.843</style></custom4></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Raval, Komal M.</style></author><author><style face="normal" font="default" size="100%">Ghormade, Vandana</style></author><author><style face="normal" font="default" size="100%">Rajamohanan, P. R.</style></author><author><style face="normal" font="default" size="100%">Choudhary, Hansraj</style></author><author><style face="normal" font="default" size="100%">Rudramurthy, Shivaprakash M.</style></author><author><style face="normal" font="default" size="100%">Chakrabarti, Arunaloke</style></author><author><style face="normal" font="default" size="100%">Paknikar, Kishore</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%"> Development of a nano-gold immunodiagnostic assay for rapid on-site detection of invasive aspergillosis </style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Medical Microbiology</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style  face="normal" font="default" size="100%">SEP</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">68</style></volume><pages><style face="normal" font="default" size="100%">1341-1352</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Introduction. Timely &lt;span class=&quot;hitHilite&quot;&gt;detection&lt;/span&gt; &lt;span class=&quot;hitHilite&quot;&gt;of&lt;/span&gt; &lt;span class=&quot;hitHilite&quot;&gt;invasive&lt;/span&gt; &lt;span class=&quot;hitHilite&quot;&gt;aspergillosis&lt;/span&gt; (IA) caused &lt;span class=&quot;hitHilite&quot;&gt;by&lt;/span&gt; fungal pathogens, i.e. Aspergillus fumigatus and Aspergillus flavus, in immunocompromised patients is crucial in preventing &lt;span class=&quot;hitHilite&quot;&gt;high&lt;/span&gt; mortality.&lt;br /&gt;
	&lt;br /&gt;
	Aim. &lt;span class=&quot;hitHilite&quot;&gt;To&lt;/span&gt; develop &lt;span class=&quot;hitHilite&quot;&gt;a&lt;/span&gt; simple immunoassay &lt;span class=&quot;hitHilite&quot;&gt;for&lt;/span&gt; &lt;span class=&quot;hitHilite&quot;&gt;the&lt;/span&gt; &lt;span class=&quot;hitHilite&quot;&gt;detection&lt;/span&gt; &lt;span class=&quot;hitHilite&quot;&gt;of&lt;/span&gt; galactomannan (GM), &lt;span class=&quot;hitHilite&quot;&gt;an&lt;/span&gt; IA biomarker.&lt;br /&gt;
	&lt;br /&gt;
	Methodology. GM from &lt;span class=&quot;hitHilite&quot;&gt;A&lt;/span&gt;. fumigatus and &lt;span class=&quot;hitHilite&quot;&gt;A&lt;/span&gt;. flavus clinical strains was purified and characterized &lt;span class=&quot;hitHilite&quot;&gt;by&lt;/span&gt; X-ray diffraction, IR spectroscopy and C-13/H-1 nuclear magnetic resonance (NMR) &lt;span class=&quot;hitHilite&quot;&gt;for&lt;/span&gt; polyclonal antibody (pAb) production in rabbits. &lt;span class=&quot;hitHilite&quot;&gt;An&lt;/span&gt; enzyme-linked immunosorbent &lt;span class=&quot;hitHilite&quot;&gt;assay&lt;/span&gt; (ELISA) was standardized using concanavalin &lt;span class=&quot;hitHilite&quot;&gt;A&lt;/span&gt; &lt;span class=&quot;hitHilite&quot;&gt;to&lt;/span&gt; capture Aspergillus GM and pAbs &lt;span class=&quot;hitHilite&quot;&gt;to&lt;/span&gt; detect it. Gold nanoparticles (AuNPs) were synthesized and conjugated &lt;span class=&quot;hitHilite&quot;&gt;to&lt;/span&gt; pAbs &lt;span class=&quot;hitHilite&quot;&gt;for&lt;/span&gt; &lt;span class=&quot;hitHilite&quot;&gt;the&lt;/span&gt; &lt;span class=&quot;hitHilite&quot;&gt;development&lt;/span&gt; &lt;span class=&quot;hitHilite&quot;&gt;of&lt;/span&gt; &lt;span class=&quot;hitHilite&quot;&gt;a&lt;/span&gt; dot-blot immunoassay. &lt;span class=&quot;hitHilite&quot;&gt;The&lt;/span&gt; developed dot-blot was evaluated with 109 clinical serum and bronchoalveolar lavage samples.&lt;br /&gt;
	&lt;br /&gt;
	Results. Spectroscopy &lt;span class=&quot;hitHilite&quot;&gt;studies&lt;/span&gt; characterized &lt;span class=&quot;hitHilite&quot;&gt;the&lt;/span&gt; D-galactofuranosyl groups &lt;span class=&quot;hitHilite&quot;&gt;of&lt;/span&gt; GM responsible &lt;span class=&quot;hitHilite&quot;&gt;for&lt;/span&gt; &lt;span class=&quot;hitHilite&quot;&gt;the&lt;/span&gt; immune response and generation &lt;span class=&quot;hitHilite&quot;&gt;of&lt;/span&gt; pAbs. &lt;span class=&quot;hitHilite&quot;&gt;The&lt;/span&gt; ELISA employing pAbs showed &lt;span class=&quot;hitHilite&quot;&gt;a&lt;/span&gt; sensitivity &lt;span class=&quot;hitHilite&quot;&gt;of&lt;/span&gt; 1 ng ml(-1) &lt;span class=&quot;hitHilite&quot;&gt;for&lt;/span&gt; Aspergillus GM. Furthermore, &lt;span class=&quot;hitHilite&quot;&gt;a&lt;/span&gt; sensitive, visual, &lt;span class=&quot;hitHilite&quot;&gt;rapid&lt;/span&gt; dot-blot &lt;span class=&quot;hitHilite&quot;&gt;assay&lt;/span&gt; developed &lt;span class=&quot;hitHilite&quot;&gt;by&lt;/span&gt; &lt;span class=&quot;hitHilite&quot;&gt;the&lt;/span&gt; conjugation &lt;span class=&quot;hitHilite&quot;&gt;of&lt;/span&gt; pAbs &lt;span class=&quot;hitHilite&quot;&gt;to&lt;/span&gt; AuNPs (similar &lt;span class=&quot;hitHilite&quot;&gt;to&lt;/span&gt; 24 +/- 5 nm size, -36 +/- 2 mV zeta potential) had &lt;span class=&quot;hitHilite&quot;&gt;a&lt;/span&gt; &lt;span class=&quot;hitHilite&quot;&gt;detection&lt;/span&gt; limit &lt;span class=&quot;hitHilite&quot;&gt;of&lt;/span&gt; 1 pg ml(-1) in serum. &lt;span class=&quot;hitHilite&quot;&gt;The&lt;/span&gt; pAbs interacted with Aspergillus spp. but did not cross-react with other fungal pathogen genera such as Penicillium and Candida. Evaluation &lt;span class=&quot;hitHilite&quot;&gt;of&lt;/span&gt; &lt;span class=&quot;hitHilite&quot;&gt;the&lt;/span&gt; dot-blot with 109 clinical samples showed &lt;span class=&quot;hitHilite&quot;&gt;high&lt;/span&gt; sensitivity (80%) and specificity (93.2 %), with &lt;span class=&quot;hitHilite&quot;&gt;an&lt;/span&gt; overall &lt;span class=&quot;hitHilite&quot;&gt;assay&lt;/span&gt; accuracy &lt;span class=&quot;hitHilite&quot;&gt;of&lt;/span&gt; 89%.&lt;br /&gt;
	&lt;br /&gt;
	Conclusion. &lt;span class=&quot;hitHilite&quot;&gt;The&lt;/span&gt; developed &lt;span class=&quot;hitHilite&quot;&gt;nano-gold&lt;/span&gt; &lt;span class=&quot;hitHilite&quot;&gt;immunodiagnostic&lt;/span&gt; &lt;span class=&quot;hitHilite&quot;&gt;assay&lt;/span&gt; has immense potential &lt;span class=&quot;hitHilite&quot;&gt;for&lt;/span&gt; practical use in &lt;span class=&quot;hitHilite&quot;&gt;rapid&lt;/span&gt;, specific and sensitive &lt;span class=&quot;hitHilite&quot;&gt;on&lt;/span&gt;-&lt;span class=&quot;hitHilite&quot;&gt;site&lt;/span&gt; diagnosis &lt;span class=&quot;hitHilite&quot;&gt;of&lt;/span&gt; IA, even under resource-limited settings.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">9</style></issue><work-type><style face="normal" font="default" size="100%">Article</style></work-type><custom3><style face="normal" font="default" size="100%">&lt;p&gt;Foreign&lt;/p&gt;
</style></custom3><custom4><style face="normal" font="default" size="100%">&lt;p&gt;&lt;span class=&quot;LrzXr kno-fv&quot;&gt;2.112&lt;/span&gt;&lt;/p&gt;
</style></custom4></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Patil, Gokul</style></author><author><style face="normal" font="default" size="100%">Torris, Arun</style></author><author><style face="normal" font="default" size="100%">Suresha, P. R.</style></author><author><style face="normal" font="default" size="100%">Jadhav, Sachin</style></author><author><style face="normal" font="default" size="100%">Badiger, V. Manohar</style></author><author><style face="normal" font="default" size="100%">Ghormade, Vandana</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Design and synthesis of a new topical agent for halting blood loss rapidly: a multimodal chitosan-gelatin xerogel composite loaded with silica nanoparticles and calcium</style></title><secondary-title><style face="normal" font="default" size="100%">Colloids and Surfaces B-Biointerfaces</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Hemostatic</style></keyword><keyword><style  face="normal" font="default" size="100%">Polymer</style></keyword><keyword><style  face="normal" font="default" size="100%">silica nanoparticles</style></keyword><keyword><style  face="normal" font="default" size="100%">Xerogel</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style  face="normal" font="default" size="100%">FEB</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">198</style></volume><pages><style face="normal" font="default" size="100%">111454</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Uncontrolled hemorrhage often causes death during traumatic injuries and halting exsanguination topically is a challenge. Here, an efficient multimodal topical hemostat was developed by (i) ionically crosslinking chitosan and gelatin with sodium tripolyphosphate for (ii) fabricating a robust, highly porous xerogel by lyophilization having 86.7 % porosity, by micro-CT and large pores similar to 30 mu m by SEM (iii) incorporating 0.5 mg synthesized silica nanoparticles (SiNPs, 120 nm size, -22 mV charge) and 2.5 mM calcium in xemgel composite that was confirmed by FTIR analysis with peaks at 3372, 986 and 788 cm(-1), respectively. XPS analysis displayed the presence of SiNPs (Si2p peak for silicon) and calcium (Ca2p1, Ca2p3 transition peaks) in the composite. Interestingly, in silico percolation simulation for composite revealed interlinked 800 mu m long-conduits predicting excellent absorption capacity and validated experimentally (640 % of composite dry weight). The composite achieved &amp;gt;16-fold improved blood clotting in vitro than commercial Celox and Gauze through multimodal interaction of its components with RBCs and platelets. The composite displayed good platelet activation and thrombin generation activities. It displayed high compressive strength (2.45 MPa) and withstood pressure during application. Moreover, xerogel composite showed high biocompatibility. In vivo application of xerogel composite to lethal femoral artery injury in rats achieved hemostasis (2.5 min) significantly faster than commercial Celox (3.3 min) and Gauze (4.6 min) and was easily removed from the wound. The gamma irradiated composite was stable till 1.5 yr. Therefore, the xerogel composite has potential for application as a rapid topical hemostatic agent.&lt;/p&gt;
</style></abstract><work-type><style face="normal" font="default" size="100%">Article</style></work-type><custom3><style face="normal" font="default" size="100%">&lt;p&gt;Foreign&lt;/p&gt;
</style></custom3><custom4><style face="normal" font="default" size="100%">5.268
</style></custom4></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Auti, Amogh</style></author><author><style face="normal" font="default" size="100%">Yadav, Pranay</style></author><author><style face="normal" font="default" size="100%">Bodkhe, Rahul</style></author><author><style face="normal" font="default" size="100%">Bhandari, Yogesh</style></author><author><style face="normal" font="default" size="100%">Varma, Sanjana</style></author><author><style face="normal" font="default" size="100%">Chaudhari, Bhushan</style></author><author><style face="normal" font="default" size="100%">Rahi, Shraddha</style></author><author><style face="normal" font="default" size="100%">Ghormade, Vandana</style></author><author><style face="normal" font="default" size="100%">Vamkudoth, Koteswara Rao</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Development of novel ssDNA aptamers for detection of receptor-binding domain of SARS-COV-2</style></title><secondary-title><style face="normal" font="default" size="100%">ACS Omega</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style  face="normal" font="default" size="100%">JUN </style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">10</style></volume><pages><style face="normal" font="default" size="100%">23981-23992</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;
	The highly virulent and transmissible SARS-CoV-2 causes COVID-19 and poses a global public health threat. Herein cloned, expressed, and the molecular weight of the receptor-binding domain (RBD) of the SARS-CoV-2 gene encoding protein was confirmed by SDS-PAGE electrophoresis and Western blot analysis. The pivotal aim is to develop single-stranded DNA (ssDNA) aptamers for the rapid detection of SARS-COV-2 infections in humans. In this investigation, a library of nine novel ssDNA aptamers was developed by several rounds of systematic evolution of ligands by an exponential enrichment approach and assessed by an enzyme-linked aptamer assay for binding affinity against RBD antigen (Ag). An in vitro assay resulted in a varied colorimetric signal that depends on the nature of aptamer. Quantitative determination of AptRBD3, AptRBD6, and AptRBD8 aptamers exhibited excellent binding affinity against Ag in the range of 5-10 ng/mL. The putative AptRBD3, AptRBD6, and AptRBD8 aptamers were converted into peptide sequences and docked against RBD, exhibiting good binding energy of -6.8, -6.3, and -7.1 kcal/mol respectively, which were recorded. Furthermore, docking studies of ssDNA aptamers were performed using HDOCK web server to ascertain the binding mechanism and docking score perceived as -389.74, -404.28, and -390.37. Despite this, we engineered a high-affinity AptRBD3.3 aptamer that formed a single and bulged loop, which improved binding affinity, resulted in a docking score of -361.56, and exhibited sensitivity at 4 ng of Ag of SARS-CoV-2. Moreover, computational modeling of AptRBD3.3 revealed an intriguing significant binding affinity with the RBD mutant SARS-CoV-2 S-UK variant (PDB ID: 7EDG) with a docking score of -350.21. In conclusion, the AptRBD3.3 aptamer can be used for the development of lateral flow device and electrochemical sensors for rapid, low-cost, and accurate detection of COVID-19 infection in humans for point of care diagnostics.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">23</style></issue><work-type><style face="normal" font="default" size="100%">Article</style></work-type><custom3><style face="normal" font="default" size="100%">&lt;p&gt;Foreign&lt;/p&gt;
</style></custom3><custom4><style face="normal" font="default" size="100%">&lt;p&gt;
	4.4&lt;/p&gt;
</style></custom4></record></records></xml>